Cambridge, MA-based Galenea Corp., a fully-integrated CNS drug discovery company, has been awarded an NIH Challenge Grant in Health and Science Research (RC1) as part of the American Recovery and Reinvestment Act of 2009.
This two-year grant from the National Institute of Mental Health addresses the specific topic of “Screening Approaches to Identify Pharmacologic Treatments for Mental Disorders” within the challenge area of Translational Science and provides approximately $1m to support the development of an innovative model for predicting the activity of potential treatments for impaired cognition in diseases such as schizophrenia.
Commenting on the grant, David Gerber, Galenea’s founder and VP of CNS Research, said, “The award serves as an endorsement of our approach to developing revolutionary analytical tools for measuring neuronal function and thereby increases the likelihood that viable drug treatments will reach the market”.
FinSMEs
06/10/2009